The US Food and Drug Administration intends to discharge direction on Tuesday illustrating its conditions for favoring an antibody for the coronavirus, the Wall Street Journal detailed, refering to a synopsis of the direction.

The organization would expect drugmakers to show "obviously illustrated" verification of an antibody's wellbeing and adequacy through a clinical report, and at any rate half more viability than a fake treatment, the report said.

There is at present no US-affirmed treatment or immunization for the respiratory sickness that has asserted more than 126,100 lives in the nation, as per a Reuters count.

In excess of 100 antibodies are being tried worldwide against the infection, with just a bunch in the human testing stage, including competitors from AstraZeneca Plc and Moderna Inc.

Specialists have recommended that it could take at least 12 to year and a half to ensure a sheltered and successful immunization through clinical preliminaries.

The direction is relied upon to be talked about by FDA Commissioner Stephen Hahn in an appearance before a Senate board on Tuesday, the report said.